Pharmacokinetics of selective β1-adrenergic blocking agents: prescribing implications

Bibliography

• Jankovic SM. Handbook of pharmacology and toxicology. 4th edition. Faculty of Medical Sciences, University of Kragujevac; Kragujevac: 2013
   Google Scholar
• Mansoor AH, Kaul U. Beta-blockers in cardiovascular medicine. J Assoc Phys India 2009;57(Supp l):7-12
   Google Scholar
• Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th edition. The McGraw-Hill Companies, Inc; New York: 2011
   Google Scholar
• Kendall MJ. Clinical relevance of pharmacokinetic differences between betablockers. Am J Cardiol 1997;80(9B)):15J-9J
   PubMed Web of Science ®Google Scholar
• De Ferrari GM, Salvati P, Grossoni M, et al. Pharmacologic modulation of the autonomic nervous system in the prevention ofsudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. J Am Coll Cardiol 1993;22(1):283-90
   PubMed Web of Science ®Google Scholar
• Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Doeslipophilicity matter? Basic Res Cardiol 2000;95(Suppl 1)):I41-5
   PubMedGoogle Scholar
• Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther 2009;31(3):447-62
   PubMed Web of Science ®Google Scholar
• Mason WD, Winer N, Kochak G, et al. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther 1979;25(4):408-15
   PubMed Web of Science ®Google Scholar
• Kirch W, Görg KG. Clinical pharmacokinetics of atenolol - a review. Eur J Drug Metab Pharmacokinet 1982;7(2):81-91
   PubMed Web of Science ®Google Scholar
• Mehvar R, Gross ME, Kreamer RN. Pharmacokinetics of atenolol enantiomers in humans and rats. J Pharm Sci 1990;79(10):881-5
   PubMed Web of Science ®Google Scholar
• Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 2001;4(2):185-200
   PubMed Web of Science ®Google Scholar
• Regårdh CG, Johnsson G, Jordö L, et al. Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. J Cardiovasc Pharmacol 1980;2(6):715-23
   PubMed Web of Science ®Google Scholar
• Regårdh CG, Landahl S, Larsson M, et al. Pharmacokinetics of metoprolol and its metabolite alpha-OH-metoprolol in healthy, non-smoking, elderly individuals. Eur J Clin Pharmacol 1983;24(2):221-6
   PubMed Web of Science ®Google Scholar
• Leopold G, Pabst J, Ungethüm W, Bühring KU. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol 1986;26(8):616-21
   PubMed Web of Science ®Google Scholar
• Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 1986;8(Suppl 11):S16-20
   PubMedGoogle Scholar
• Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997;51(6):493-8
   PubMed Web of Science ®Google Scholar
• Veverka A, Salinas JL. Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag 2007;3(5):647-54
   PubMedGoogle Scholar
• Angaran DM, Schultz NJ, Tschida VH. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent. Clin Pharm 1986;5(4):288-303
   PubMedGoogle Scholar
• Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F. Pharmacokinetics of acebutolol enantiomers in humans. J Pharm Sci 1991;80(4):313-16
   PubMed Web of Science ®Google Scholar
• Roux A, Henry JF, Fouache Y, et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology 1983;29(3):202-8
   PubMed Web of Science ®Google Scholar
• Cerqueira PM, Cesarino EJ, Mateus FH, et al. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. Chirality 1999;11(7):591-7
   PubMed Web of Science ®Google Scholar
• Stagni G, Davis PJ, Ludden TM. Human pharmacokinetics of betaxolol enantiomers. J Pharm Sci 1991;80(4):321-4
   PubMed Web of Science ®Google Scholar
• Frishman WH, Tepper D, Lazar EJ, Behrman D. Betaxolol: a new long-acting beta 1-selective adrenergic blocker. J Clin Pharmacol 1990;30(8):686-92
   PubMed Web of Science ®Google Scholar
• Borchard U. Pharmacological properties ofbeta-adrenoceptor blocking drugs. J Clin Bas Cardiol 1998;1(1):5-9
   Google Scholar
• Drayer DE. Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. Pharmacotherapy 1987;7(4):87-91
   PubMed Web of Science ®Google Scholar
• McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther 1990;46(2):163-97
   PubMed Web of Science ®Google Scholar
• Neil-Dwyer G, Bartlett J, McAinsh J, Cruickshank JM. Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol 1981;11(6):549-53
   PubMed Web of Science ®Google Scholar
• López-Sendón J, Swedberg K, McMurray J, et al. Task ForceOnBeta-Blockers of the European Society of Cardiology. Expert consensus document onbeta-adrenergic receptor blockers. Eur Heart J 2004;25(15):1341-62
   PubMed Web of Science ®Google Scholar
• Cheymol G, Poirier JM, Carrupt PA, et al. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 1997;43(6):563-70
   PubMed Web of Science ®Google Scholar
• Lakshmi N, VasantDnyandeo B. Physico-chemical characterization of some beta blockers and anti-diabetic drugs - potentiometric and spectrophotometric pKa determination in different co-solvents. Eur J Chem 2011;2(1):36-46
   Google Scholar
• Carona G, Steyaerta G, Pagliaraa A, et al. Structure-Lipophilicity Relationships of Neutral and Protonated b-Blockers. Part I. Intra- and Intermolecular Effects in Isotropic Solvent Systems. Helvetica Chimica Acta 1999;82:1211-22
   Web of Science ®Google Scholar
• Samuels TL, Uncles DR, Willers JW, et al. Logging the potential for intravenous lipid emulsion in propranolol and other lipophilic drug overdoses. Anaesthesia 2011;66(3):221-2
   PubMed Web of Science ®Google Scholar
• Kadam RS, Kompella UB. Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J Pharmacol Exp Ther 2010;332(3):1107-20
   PubMed Web of Science ®Google Scholar
• Carda-Broch S, Berthod A. pH dependence of the hydrophobicity of beta-blocker amine compounds measured by counter-current chromatography. J Chromatogr A 2003;995(1-2):55-66
   PubMed Web of Science ®Google Scholar
• Tetko IV, Tanchuk VY, Villa AE. Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf Comput Sci 2001;41:1407-21
   PubMedGoogle Scholar
• Goldner JA. Metoprolol-induced visual hallucinations: a case series. J Med Case Rep 2012;6(1):65
   Google Scholar
• Ahmed AI, van Mierlo PJ, van Waarde JA, Jansen PA. Hallucinations and vividdreams by use of metoprolol. Tijdschr Psychiatr 2010;52(2):117-21
   PubMedGoogle Scholar
• Mason WD, Winer N, Kochak G, et al. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther 1979;25(4):408-15
   PubMed Web of Science ®Google Scholar
• Kaye CM, Kumana CR, Leighton M, et al. Observations on the pharmacokinetics of acebutolol. Clin Pharmacol Ther 1976;19(4):416-20
   PubMed Web of Science ®Google Scholar
• Schmidt P, Takacs F, Pittner H, et al. Comparative pharmacokinetics of the beta-1 receptor blookaderceliprolol after a single oral administration in subjects with health kidneys and in patients with impaired renal function. Wien Klin Wochenschr 1985;97(18):729-32
   PubMed Web of Science ®Google Scholar
• Jordö L, Attman PO, Aurell M, et al. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet 1980;5(2):169-80
   PubMed Web of Science ®Google Scholar
• Payton CD, Fox JG, Pauleau NF, et al. The single dose pharmacokinetics of bisoprolol (10 mg) in renal insufficiency: the clinical significance of balanced clearance. Eur Heart J 1987;8(Suppl M):15-22
   PubMedGoogle Scholar
• Höcht C, Bertera FM, Del Mauro JS, Taira CA. Models for evaluating thepharmacokinetics and pharmacodynamics for β-blockers. Expert Opin Drug Metab Toxicol 2014;10(4):525-41
   PubMed Web of Science ®Google Scholar
• Hartmann C, Frölich M, Krauss D, et al. Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal function. Eur J Clin Pharmacol 1990;39(6):573-6
   PubMed Web of Science ®Google Scholar
• Palminteri R, Assael BM, Bianchetti G, et al. Betaxolol kinetics in hypertensive children with normal and abnormal renal function. Clin Pharmacol Ther 1984;35(2):141-7
   PubMed Web of Science ®Google Scholar
• Hoffmann KJ, Regårdh CG, Aurell M, et al. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet 1980;5(2):181-91
   PubMed Web of Science ®Google Scholar
• Wiest D. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet 1995;28(3):190-202
   PubMed Web of Science ®Google Scholar
• Cohen-Solal A, Kotecha D, van Veldhuisen DJ, et al. SENIORS Investigators. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009;11(9):872-80
   PubMed Web of Science ®Google Scholar
• McAinsh J, Holmes BF, Smith S, et al. Atenolol kinetics in renal failure. Clin Pharmacol Ther 1980;28(3):302-9
   PubMed Web of Science ®Google Scholar
• Smith RS, Warren DJ, Renwick AG, George CF. Acebutolol pharmacokinetics in renal failure. Br J Clin Pharmacol 1983;16(3):253-8
   PubMed Web of Science ®Google Scholar
• Pruss TP, Lamon KD, Hagen NS. Celiprolol - overview of 6 years of clinical trials experience. J Int Med Res 1988;16(Suppl 1):17A-22A
   PubMedGoogle Scholar
• Stajić M, Granger RH, Beyer JC. Fatal metoprolol overdose. J Anal Toxicol 1984;8(5):228-30
   PubMed Web of Science ®Google Scholar
• Bühring KU, Sailer H, Faro HP, et al. Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans. J Cardiovasc Pharmacol 1986;8(Suppl 11):S21-8
   PubMedGoogle Scholar
• Ryan JR. Clinical pharmacology of acebutolol. Am Heart J 1985;109(5 Pt 2):1131-6
   PubMed Web of Science ®Google Scholar
• Reeves PR, McAinsh J, McIntosh DA, Winrow MJ. Metabolism of atenolol in man. Xenobiotica 1978;8(5):313-20
   PubMed Web of Science ®Google Scholar
• Winkle RA, Meffin PJ, Ricks WB, Harrison DC. Acebutolol metabolite plasma concentration during chronic oral therapy. Br J Clin Pharmacol 1977;4(5):519-22
   PubMed Web of Science ®Google Scholar
• Ohashi K, Warrington SJ, Kaye CM, et al. Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol. Br J Clin Pharmacol 1981;12(4):561-5
   PubMed Web of Science ®Google Scholar
• Milne RJ, Buckley MM. Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease. Drugs 1991;41(6):941-69
   PubMed Web of Science ®Google Scholar
• Wellstein A, Palm D, Belz GG, et al. Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. J Cardiovasc Pharmacol 1986;8(Suppl 11):S41-5
   PubMedGoogle Scholar
• Horikiri Y, Suzuki T, Mizobe M. Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci 1998;63(13):1097-108
   PubMed Web of Science ®Google Scholar
• Wong YW, Ludden TM. Determination of betaxolol and its metabolites in blood and urine by high-performance liquid chromatography with fluorimetric detection. J Chromatogr 1990;534:161-72
   PubMed Web of Science ®Google Scholar
• Minushkina LO, Zateishchikova AA, Zateishchikov DA, et al. Genetic aspects of individual sensitivity to betaxolol in patients with arterial hypertension. Kardiologiia 2008;48(3):20-6
   PubMed Web of Science ®Google Scholar
• Blake CM, Kharasch ED, Schwab M, Nagele P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther 2013;94(3):394-9
   PubMed Web of Science ®Google Scholar
• Xu T, Bao S, Geng P, et al. Determination of metoprolol and its two metabolites in human plasma and urine by high performance liquid chromatography with fluorescence detection and its application in pharmacokinetics. J Chromatogr B AnalytTechnol Biomed Life Sci 2013;937:60-6
   PubMed Web of Science ®Google Scholar
• Ebihara A, Fujimura A. Metabolites of antihypertensive drugs. An updated review of their clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1991;21(5):331-43
   PubMed Web of Science ®Google Scholar
• Prisant LM. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker. J Clin Pharmacol 2008;48(2):225-39
   PubMed Web of Science ®Google Scholar
• Jahn P, Eckrich B, Schneidrowski B, et al. Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor. Arzneimittelforschung 1995;45(5):536-41
   PubMed Web of Science ®Google Scholar
• Talbert RL. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail Rev 2004;9(2):131-7
   PubMed Web of Science ®Google Scholar
• Nikolic VN, Jevtovic-Stoimenov T, Velickovic-Radovanović R, et al. Population pharmacokinetics of bisoprolol in patients with chronic heart failure. Eur J Clin Pharmacol 2013;69(4):859-65
   PubMed Web of Science ®Google Scholar
• Taguchi M, Nozawa T, Igawa A, et al. Pharmacokinetic variability of routinely administered bisoprolol in middle-aged and elderly Japanese patients. Biol Pharm Bull 2005;28(5):876-81
   PubMed Web of Science ®Google Scholar
• Grevel J, Thomas P, Whiting B. Population pharmacokinetic analysis of bisoprolol. Clin Pharmacokinet 1989;17(1):53-63
   PubMed Web of Science ®Google Scholar
• Hayes PC, Jenkins D, Vavianos P, et al. Single oral dose pharmacokinetics of bisoprolol 10 mg in liver disease. Eur Heart J 1987;8(Suppl M):23-9
   PubMedGoogle Scholar
• Rey E, Jammet P, d’Athis P, et al. Effect of cimetidine on the pharmacokinetics of the new beta-blocker betaxolol. Arzneimittelforschung 1987;37(8):953-6
   PubMed Web of Science ®Google Scholar
• Jin SK, Chung HJ, Chung MW, et al. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. J Clin Pharm Ther 2008;33(5):567-73
   PubMed Web of Science ®Google Scholar
• Taguchi M, Nozawa T, Mizumaki K, et al. Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients. Biol Pharm Bull 2004;27(10):1642-8
   PubMed Web of Science ®Google Scholar
• Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997;51(6):493-8
   PubMed Web of Science ®Google Scholar
• Ieiri I, Doi Y, Maeda K, et al. Microdosing clinical study: pharmacokinetic,pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles ofceliprolol following the oral microdose and therapeutic dose. J Clin Pharmacol 2012;52(7):1078-89
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Niemi M, Neuvonen PJ. Rifampicinreduces plasma concentrations of celiprolol. Eur J Clin Pharmacol 2004;59(11):819-24
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on thepharmacokinetics of atenolol. Eur J Clin Pharmacol 2005;61(5-6):337-40
   PubMed Web of Science ®Google Scholar
• Shirasaka Y, Shichiri M, Mori T, et al. Major active components in grapefruit, orange, and apple juices responsible for OATP2B1-mediated drug interactions. J Pharm Sci 2013;102(9):3418-26
   PubMed Web of Science ®Google Scholar
• Kirch W, Spahn H, Ohnhaus EE, et al. Influence ofinflammatory disease on the clinical pharmacokinetics of atenolol and metoprolol.Biopharm Drug Dispos. 1983;4(1):73-81
   Google Scholar
• Hallengren B, Nilsson OR, Karlberg BE, et al. Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol. Eur J Clin Pharmacol 1982;21(5):379-84
   PubMed Web of Science ®Google Scholar
• Roux A, Henry JF, Fouache Y, et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology 1983;29(3):202-8
   PubMed Web of Science ®Google Scholar
• Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F. Effect of aging on the pharmacokinetics of acebutolol enantiomers. J Clin Pharmacol 1992;32(2):148-56
   PubMed Web of Science ®Google Scholar